September 20, 2018
- CDER Statement: FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis
- Director's Corner Podcast: Drug Shortages--Transcript
- Director’s Corner Podcast: Drug Shortages--Podcast
- FDA Drug Shortages
- Procainamide Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Small Business Chronicle: "Real-Time Review of Drug Applications is Now a Reality" September 20, 2018 Issue
.png)
No hay comentarios:
Publicar un comentario